Author

H.-i. Tsai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

F. Cheng· 2 shared H. Chen· 2 shared L. Wang· 2 shared X. Liu· 2 shared Z. Xu· 2 shared B. Jia· 1 shared C. He· 1 shared C. Wang· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Cheng

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 28, 2022

TRAF6 modulates PD-L1 expression through YAP1-TFCP2 signaling in melanoma

X. Liu, L. Wang, Y. Han…·F. Cheng

This study identifies TRAF6 as a regulator of PD-L1 expression in melanoma through YAP1-TFCP2 signaling, showing TRAF6 inhibition enhances anti-tumor immunity.

DOI 10.1101/2022.09.28.509909

humanexperimental assay

𝕏 PostBluesky

BioengineeringAdvanced SciencePeer-reviewedNov 5, 2021

Engineered small extracellular vesicles as a FGL1/PD-L1 dual-targeting delivery system for alleviating immune rejection

H.-i. Tsai, Y. Wu, X. Liu…·H. Chen

This study develops engineered small extracellular vesicles targeting FGL1 and PD-L1 to suppress immune rejection in transplantation by inhibiting T cell activation and improving graft survival.

DOI 10.1002/advs.202102634

mouseexperimental assay

𝕏 PostBluesky